πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Legend Biotech Corporation

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. logo
Market Cap: Low
Employees: Low

LYL797, LYL845, NY-ESO-1

Lyell Immunopharma, Inc. is a biopharmaceutical company developing T cell therapies focused on treating patients with solid tumors using advanced genetic and epigenetic reprogramming technologies.

Tags: T cell therapy, biotechnology, cancer treatment, epigenetic reprogramming, genetic reprogramming, solid tumors

Symbol: LYEL

Recent Price: $0.62

Industry: Biotechnology

CEO: Dr. Lynn Seely M.D., Ph.D.

Sector: Healthcare

Employees: 224

Address: 201 Haskins Way, South San Francisco, CA 94080

Phone: 650 695 0677

Leadership

  • Lynn Seely, M.D., President & Chief Executive Officer
  • Stephen Hill, Chief Operating Officer
  • Matthew Lang, J.D., Chief Business Officer
  • Gary Lee, Ph.D., Chief Scientific Officer
  • Charles Newton, Chief Financial Officer
  • Ellen Rose, Senior Vice President, Investor Relations and Communications
  • Bryan Selby, Senior Vice President, Clinical Development Operations
  • Ann Tomlin, Senior Vice President, Human Resources
  • Rick Klausner, M.D., Founder & Board Chair
  • Crystal Mackall, M.D., Founder
  • Stan Riddell, M.D., Founder
  • Hans Bishop, Director
  • Otis Brawley, M.D., Director
  • Catherine Friedman, Director
  • Elizabeth Nabel, M.D., Director
  • Robert Nelsen, Director
  • William Rieflin, Director

Last updated: 2024-12-31

Mustang Bio, Inc.

Mustang Bio, Inc. logo
Market Cap: Lowest
Employees: Low

Gene and CAR T Cell Therapies

Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. It focuses on developing gene therapy programs and CAR T cell therapies, including treatments for X-linked severe combined immunodeficiency and various types of cancer.

Tags: CAR T cell, biopharmaceutical, gene therapy, genetic diseases, hematologic cancers, solid tumors

Symbol: MBIO

Recent Price: $0.19

Industry: Biotechnology

CEO: Dr. Manuel Litchman M.D.

Sector: Healthcare

Employees: 80

Address: 377 Plantation Street, Worcester, MA 01605

Phone: 781 652 4500

Leadership

  • Manuel Litchman, M.D., President, Chief Executive Officer and Director
  • Greg Furrow, M.S., FRQA, Chief Quality Officer
  • James Murphy, B.A., Ad interim Chief Financial Officer
  • Michael S. Weiss, Chairman of the Board of Directors
  • Lindsay A. Rosenwald, M.D., Director
  • Adam J. Chill, Director
  • Neil Herskowitz, Director
  • Michael J. Zelefsky, M.D., Director
  • Mustang Bio, Inc., Company

Last updated: 2024-12-31

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB-100 series and LB-200 series

Lixte Biotechnology Holdings, Inc. is a drug discovery company leveraging biomarker technology to develop enzyme-targeting drugs for cancer, vascular, metabolic, hereditary, and neurodegenerative diseases.

Tags: biomarker technology, biotechnology, cancer treatment, drug discovery, enzyme targets

Symbol: LIXT

Recent Price: $2.00

Industry: Biotechnology

CEO: Mr. Bastiaan van der Baan M.Sc.

Sector: Healthcare

Employees: 3

Address: 680 East Colorado Boulevard, Pasadena, CA 91101

Phone: 631 830 7092

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

ORLADEYO

Bio Cryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering novel, oral, and small-molecule medicines, with marketed products including RAPIVAB and ORLADEYO, and a pipeline featuring BCX9930, BCX9250, and Galidesivir.

Tags: biotechnology, clinical trials, hereditary angioedema, influenza treatment, oral medicines, small-molecule medicines

Symbol: BCRX

Recent Price: $7.53

Industry: Biotechnology

CEO: Mr. Jon P. Stonehouse

Sector: Healthcare

Employees: 536

Address: 4505 Emperor Boulevard, Durham, NC 27703

Phone: 919 859 1302

Last updated: 2024-12-31

Belite Bio, Inc

Belite Bio, Inc logo
Market Cap: High
Employees: Lowest

LBS-008

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics for age-related macular degeneration and Stargardt diseases. Its lead product candidate, LBS-008, is in phase 3 clinical trials.

Tags: Stargardt diseases, biopharmaceutical, clinical-stage, drug development, liver disease, macular degeneration, phase 3, therapeutics

Symbol: BLTE

Recent Price: $61.97

Industry: Biotechnology

CEO: Dr. Yu-Hsin Lin M.B.A., Ph.D.

Sector: Healthcare

Employees: 20

Address: 5820 Oberlin Drive, San Diego, CA 92121

Phone: 858-246-6240

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

CLR 131

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.

Tags: biopharmaceutical, cancer treatment, drug development, phospholipid drug conjugate

Symbol: CLRB

Recent Price: $0.29

Industry: Biotechnology

CEO: Mr. James V. Caruso

Sector: Healthcare

Employees: 20

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 608 441 8120

Leadership

  • James Caruso, President, CEO and Director
  • Chad Kolean, Chief Financial Officer
  • Shane Lea, Chief Commercial Officer
  • Jarrod Longcor, Chief Operating Officer
  • Andrei Shustov, Senior Vice President, Medical
  • Douglas J. Swirsky, Chairman of the Board
  • Asher Alban Chanan-Khan, MD., Director
  • Frederick W. Driscoll, Director
  • Stefan D. Loren, Ph.D., Director
  • John Neis, Director
  • Cellectar Biosciences, Inc., Company Information

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. logo
Market Cap: High
Employees: Medium

lifileucel

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to utilize the immune system in eradicating cancer cells, with several ongoing phase 2 clinical studies.

Tags: biotechnology, cancer immunotherapy, cancer treatment, clinical-stage, lifileucel

Symbol: IOVA

Recent Price: $7.17

Industry: Biotechnology

CEO: Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Sector: Healthcare

Employees: 557

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 260 7120

Last updated: 2024-12-31

Legend Biotech Corporation

Legend Biotech Corporation logo
Market Cap: Highest
Employees: High

LCAR-B38M

Legend Biotech Corporation is a clinical-stage biopharmaceutical company focusing on the discovery and development of novel cell therapies for oncology and other indications globally.

Tags: CAR-T, biopharmaceutical, cell therapy, clinical trials, lymphoma, multiple myeloma, oncology

Symbol: LEGN

Recent Price: $32.77

Industry: Biotechnology

CEO: Dr. Ying Huang Ph.D.

Sector: Healthcare

Employees: 2200

Address: 2101 Cottontail Lane, Somerset, NJ 08873

Phone: 732 317 5050

Leadership

  • Ying Huang, Ph.D., CHIEF EXECUTIVE OFFICER
  • Guowei Fang, Ph.D., CHIEF SCIENTIFIC OFFICER AND HEAD OF BUSINESS DEVELOPMENT
  • Lori Macomber, CHIEF FINANCIAL OFFICER
  • Mythili Koneru, M.D., Ph.D., CHIEF MEDICAL OFFICER
  • Jim Pepin, GENERAL COUNSEL
  • Steve Gavel, SENIOR VICE PRESIDENT, COMMERCIAL DEVELOPMENT, US & EUROPE
  • Yuhong Qiu, Ph.D., SENIOR VICE PRESIDENT, GLOBAL REGULATORY AFFAIRS
  • Birk VanderweeΓ«n, SENIOR VICE PRESIDENT, GLOBAL MANUFACTURING & SUPPLY
  • Alan Kick, SENIOR VICE PRESIDENT, GLOBAL QUALITY
  • Doug Wallace, VICE PRESIDENT, GLOBAL OPERATIONS
  • Elaine Qian, VICE PRESIDENT, GLOBAL HEAD OF HUMAN RESOURCES
  • Tim Roberts, Global Compliance Officer
  • Simon Wu, Senior Vice President, General Manager, Greater China
  • Frank Zhang, EMBA, Ph.D., CHAIRMAN OF THE BOARD, LEGEND BIOTECH
  • Sally Wang, M.S., PRESIDENT, GENSCRIPT
  • Zhu Li, Ph.D., CHIEF STRATEGY OFFICER, GENSCRIPT
  • Corazon (Corsee) Dating Sanders, Ph.D., CO-CHAIR OF THE BOARD OF ADVISORS, FRED HUTCH CANCER CENTER
  • Darren Ji, M.D., Ph.D. and MBA, CHAIRMAN AND CEO, ELPISCIENCE BIOPHARMACEUTICALS
  • Philip Yau, CHIEF FINANCIAL OFFICER. C&J CLARK
  • Patrick Casey, Ph.D., SENIOR VICE DEAN OF RESEARCH, DUKE-NUS MEDICAL SCHOOL SINGAPORE AND A JAMES B. DUKE PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY, DUKE UNIVERSITY
  • Tomas J. Heyman, CEO, INTERLAKEN THERAPEUTICS
  • Li Mao, M.D., CHIEF MEDICAL OFFICER, SCICLONE PHARMACEUTICALS
  • Peter Salovey, Ph.D., Chris Argyris Professor of Psychology; Professor of Management, Epidemiology & Public Health, and Sociology; and President Emeritus of Yale University
  • Michel Vounatsos, FORMER CEO OF BIOGEN INC.
  • John Maraganore, Ph.D., FORMER CEO OF ALNYLAM PHARMACEUTICALS

Last updated: 2024-12-31

Longeveron Inc.

Longeveron Inc. logo
Market Cap: Lowest
Employees: Lowest

LOMECEL-B

Longeveron Inc. is a biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. Its leading product, LOMECEL-B, undergoes clinical trials for various serious health indications.

Tags: LOMECEL-B, aging-related conditions, biotechnology, cellular therapies, clinical stage, clinical trials

Symbol: LGVN

Recent Price: $1.77

Industry: Biotechnology

CEO: Mr. Mohamed Wa'el Ahmed Hashad M.B.A.

Sector: Healthcare

Employees: 23

Address: 1951 NW 7th Avenue, Miami, FL 33136

Phone: 305 909 0840

Leadership

  • Wa'el Hashad, Chief Executive Officer
  • K. Chris Min, MD, Ph.D., Acting Chief Medical Officer
  • Joshua M. Hare, MD, FACC, FAHA, Chairman, Chief Science Officer
  • Lisa Locklear, Chief Financial Officer
  • Nataliya Agafonova, MD, Chief Medical Officer
  • James Clavijo, Acting Chief Financial Officer
  • Paul Lehr, JD, General Counsel and Secretary
  • Lisa McClain-Moss, Vice President, Manufacturing
  • Jerome Bailey, Vice President of Business Operations
  • Elly Ryu, Vice President & Corporate Controller
  • Brian Rash, Vice President of Research & Discovery
  • Mike Mannarino, Vice President and Corporate Controller
  • Tavara Andrews, Vice President & Corporate Controller
  • Anthony Oliva, Ph.D., Senior Scientist
  • Dan Gincel, Ph.D., Senior VP, Strategic Collaborations & Scientific Affairs
  • Dr. Kevin Ramdas, Director, Clinical Operations
  • Kwan-Hong Chris Min, Acting Chief Medical Officer
  • Donald M. Soffer, Board of Directors
  • Khoso Baluch, Independent Director
  • Jeffrey Pfeffer, Board of Directors
  • Richard Kender, Board of Directors
  • Neil E. Hare, JD, Board of Directors
  • Rock Soffer, Board of Directors
  • Douglas Losordo, MD, Board of Directors
  • Erin Borger, Board of Directors
  • Cathy Ross, Board of Directors
  • Ursula Ungaro, Board of Directors
  • Neha Motwani, Board of Directors
  • Roger Hajjar, MD, Board of Directors
  • Todd Girolamo, JD, MBA, Board of Directors

Last updated: 2024-12-31

LogicBio Therapeutics, Inc.

LogicBio Therapeutics, Inc. logo
Market Cap: Low
Employees: Medium

LB-001

Logic Bio Therapeutics, Inc. is a genetic medicine company focused on genome editing and gene therapy treatments using its Gene Ride and s AAVy platforms. Its lead product candidate, LB-001, is in clinical trials for methylmalonic acidemia.

Tags: Gene Ride, LB-001, gene therapy, genetic medicine, genome editing, methylmalonic acidemia, s AAVy

Symbol: LOGC

Recent Price: $7.08

Industry: Biotechnology

CEO: Mr. Rishi Bajaj

Sector: Healthcare

Employees: 452

Address: 65 Hayden Ave, 2Nd Floor, Lexington, MASSACHUSETTS 02421

Phone: 16172450399

Last updated: 2024-12-31

Palisade Bio, Inc.

Palisade Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB1148

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral therapies targeting serious diseases related to the breakdown of the gastrointestinal mucosal barrier. Their lead product, LB1148, is designed to protect gut integrity during intestinal stress.

Tags: LB1148, biopharmaceutical, clinical-stage, gastrointestinal health, mucosal barrier, oral therapies

Symbol: PALI

Recent Price: $1.70

Industry: Biotechnology

CEO: Mr. J. D. Finley

Sector: Healthcare

Employees: 9

Address: 5800 Armada Drive, Carlsbad, CA 92008

Phone: 858 704 4900

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

XCART

Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on advancing XCART, a personalized CAR T platform technology for oncology therapeutics and biologic drug development.

Tags: CAR T, biopharmaceutical, biotechnology, drug delivery, oncology, therapeutics

Symbol: XBIO

Recent Price: $4.05

Industry: Biotechnology

CEO: Mr. James F. Parslow

Sector: Healthcare

Employees: 4

Address: 40 Speen Street, Framingham, MA 01701

Phone: 781 778 7720

Leadership

  • James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
  • Scott N. Cullison, Business Development
  • Reid P. Bissonnette, Ph.D., Translational Research and Development
  • Cory C. Kauffman, Ph.D., Chief Technology Officer
  • Adam Logal, Chairman
  • Grigory G. Borisenko, Ph.D., Non-Executive Director
  • James Eric Callaway, Ph.D., Non-Executive Director
  • Firdaus Jal Dastoor, FCS, Non-Executive Director
  • Dmitry Genkin, MD, Non-Executive Director
  • Roger Kornberg, Ph.D., Non-Executive Director
  • Moshe Mizrahy, Non-Executive Director
  • Dr. Alexey Vinogradov, Non-Executive Director

Last updated: 2024-12-31

IN8bio, Inc.

IN8bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

INB-200, INB-100, INB-400, INB-300

IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.

Tags: biopharmaceutical, biotechnology, cancer treatment, clinical trials, gamma-delta T cell therapies

Symbol: INAB

Recent Price: $0.27

Industry: Biotechnology

CEO: Mr. Tai-Wei Ho

Sector: Healthcare

Employees: 39

Address: 350 5th Avenue, New York, NY 10118

Phone: 646 600 6438

Last updated: 2024-12-31

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

CTI-1601

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for rare diseases using a novel cell penetrating peptide technology platform. Their lead product candidate, CTI-1601, is undergoing Phase 1 clinical trials to treat Friedreich's ataxia.

Tags: Friedreich's ataxia, biotechnology, cell penetrating peptide, clinical-stage, novel technologies, rare diseases

Symbol: LRMR

Recent Price: $3.91

Industry: Biotechnology

CEO: Dr. Carole S. Ben-Maimon M.D.

Sector: Healthcare

Employees: 42

Address: Three Bala Plaza East, Bala Cynwyd, PA 19004

Phone: 844 511 9056

Leadership

  • Carole Ben-Maimon, MD, President and Chief Executive Officer
  • Gopi Shankar, PhD, MBA, FAAPS, Chief Development Officer
  • Rusty Clayton, DO, Chief Medical Officer
  • Michael Celano, CHIEF FINANCIAL OFFICER
  • John Berman, Vice President of Finance and Administration
  • Jennifer Johansson, Vice President, Legal and Compliance
  • Keith E. Lynch, Jr., Vice President, CMC Technical Operations
  • Noreen Scherer, Vice President of Clinical Operations
  • Francis Michael Conway, CPA, VICE PRESIDENT AND CONTROLLER
  • Mohamed Hamdani, Vice President, Statistics and Quantitative Sciences
  • Adrienne Clements-Egan, Ph.D., Vice President, Bioanalytics and Developability
  • Frank Nazzario, RPh, Vice President, Commercial
  • Joseph Truitt, BOARD CHAIR
  • Tom Hamilton,
  • Jonathan Leff,
  • Frank E. Thomas,
  • Jeffrey Sherman, MD,
  • ,

Last updated: 2024-12-31